Acadia Pharmaceuticals (ACAD) PT Lowered to $19 at Oppenheimer, 'We now expect ACAD to optimize FCF generation with Nuplazid'
Tweet Send to a Friend
(Updated - March 12, 2024 9:18 AM EDT)
Oppenheimer analyst Jay Olson lowered the price target on Acadia Pharmaceuticals ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Oppenheimer analyst Jay Olson lowered the price target on Acadia Pharmaceuticals ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
